NEUROCRINE BIOSCIENCES (NBIX) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$142.44
+0.8% on the day
+2.9% over 12 months
52-week range $123.10 – $185.50
Share price and insider trades
NBIX closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$77.9M
Insiders buying0
Insiders selling15
NEUROCRINE BIOSCIENCES insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 15 sold $77.9M of NBIX stock on the open market.
Get emailed when insiders cluster-buy stocks like NBIX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
NBIX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $6.2M | 9 |
| Q2 2026 | — | 0 | $57.0M | 21 |
| Q1 2026 | — | 0 | $4.8M | 2 |
| Q4 2025 | — | 0 | $9.8M | 8 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.0×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 NEUROCRINE BIOSCIENCES INC insiders reported open-market purchases totaling $0, while 15 insiders reported sales totaling $77.9M. 40 of 40 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 15SEC | Matt AbernethyCFO | Sell Plan | 2,31142,808 held (−5%) | $157.20 | $363K | -9.4% | — |
| Sep 15SEC | David W. BoyerChief Corp. Affairs Officer | Sell Plan | 8268,722 held (−9%) | $157.45 | $130K | -9.5% | — |
| Sep 10SEC | Eric BenevichChief Commercial Officer | Sell Plan | 2,15464,408 held (−3%) | $154.61 | $333K | -7.9% | — |
| Jul 30SEC | Leslie V NorwalkDirector | Sell Plan | 1,2501,588 held (−44%) | $182.01 | $228K | -21.7% | — |
| Jul 13SEC | Darin LippoldtGeneral Counsel | Sell Plan | 10,00054,729 held (−15%) | $179.60 | $1.8M | -20.7% | — |
| Jul 13SEC | Ingrid DelaetChief Regulatory Officer | Sell Plan | 4,36716,225 held (−21%) | $181.02 | $791K | -21.3% | — |
| Jul 9SEC | Ingrid DelaetChief Regulatory Officer | Sell Plan | 8,43316,225 held (−34%) | $178.72 | $1.5M | -20.3% | — |
| Jul 9SEC | Ingrid DelaetChief Regulatory Officer | Sell Plan | 3,40116,225 held (−17%) | $178.57 | $607K | -20.2% | — |
| Jul 9SEC | Ingrid DelaetChief Regulatory Officer | Sell Plan | 2,73716,225 held (−14%) | $178.54 | $489K | -20.2% | — |
| Jun 30SEC | Darin LippoldtGeneral Counsel | Sell Plan | 8,11054,729 held (−13%) | $170.03 | $1.4M | -16.2% | — |
| Jun 30SEC | Darin LippoldtGeneral Counsel | Sell Plan | 1,69054,729 held (−3%) | $170.81 | $289K | -16.6% | — |
| Jun 30SEC | Darin LippoldtGeneral Counsel | Sell Plan | 20054,729 held (−0%) | $169.57 | $34K | -16.0% | — |
| Jun 9SEC | Stephen A SherwinDirector | Sell Plan | 7,88332,977 held (−19%) | $163.81 | $1.3M | -13.0% | — |
| Jun 9SEC | Stephen A SherwinDirector | Sell Plan | 6,89623,532 held (−23%) | $165.79 | $1.1M | -14.1% | — |
| Jun 9SEC | Stephen A SherwinDirector | Sell Plan | 5,82917,703 held (−25%) | $166.56 | $971K | -14.5% | — |
| Jun 9SEC | Stephen A SherwinDirector | Sell Plan | 2,54930,428 held (−8%) | $164.44 | $419K | -13.4% | — |
| Jun 9SEC | Stephen A SherwinDirector | Sell Plan | 1,84315,860 held (−10%) | $167.31 | $308K | -14.9% | — |
| Jun 8SEC | Leslie V NorwalkDirector | Sell Plan | 1,2502,838 held (−31%) | $168.06 | $210K | -15.2% | — |
| Jun 4SEC | Julie CookeChief Human Resources Officer | Sell Plan | 14,21445,097 held (−24%) | $154.83 | $2.2M | -8.0% | — |
| Jun 4SEC | Julie CookeChief Human Resources Officer | Sell Plan | 9,52125,894 held (−27%) | $157.62 | $1.5M | -9.6% | — |
| Jun 4SEC | Julie CookeChief Human Resources Officer | Sell Plan | 5,46639,631 held (−12%) | $155.46 | $850K | -8.4% | — |
| Jun 4SEC | Julie CookeChief Human Resources Officer | Sell Plan | 4,21635,415 held (−11%) | $156.77 | $661K | -9.1% | — |
| Jun 4SEC | Julie CookeChief Human Resources Officer | Sell Plan | 3,52022,374 held (−14%) | $158.59 | $558K | -10.2% | — |
| Jun 2SEC | Jude OnyiaChief Scientific Officer | Sell Plan | 11,00025,846 held (−30%) | $160.25 | $1.8M | -11.1% | — |
| Jun 2SEC | Ingrid DelaetChief Regulatory Officer | Sell Plan | 2,26116,225 held (−12%) | $156.71 | $354K | -9.1% | — |
| May 29SEC | Jude OnyiaChief Scientific Officer | Sell Plan | 11,00025,846 held (−30%) | $155.53 | $1.7M | -8.4% | — |
| May 28SEC | David W. BoyerChief Corp. Affairs Officer | Sell Plan | 3,8887,799 held (−33%) | $156.64 | $609K | -9.1% | — |
| May 21SEC | Kevin Charles GormanDirector | Sell Plan | 245,088511,293 held (−32%) | $154.33 | $37.8M | -7.7% | — |
| May 18SEC | Richard F PopsDirector | Sell Plan | 15,00034,480 held (−30%) | $157.65 | $2.4M | -9.6% | — |
| May 14SEC | Leslie V NorwalkDirector | Sell Plan | 3,8102,429 held (−61%) | $155.01 | $591K | -8.1% | — |
| Jan 20SEC | Kyle GanoCEO | Sell Plan | 34,588140,407 held (−20%) | $132.70 | $4.6M | +7.3% | — |
| Jan 20SEC | Kyle GanoCEO | Sell Plan | 1,812140,407 held (−1%) | $132.71 | $240K | +7.3% | — |
| Dec 17SEC | Leslie V NorwalkDirector | Sell Plan | 5,0007,429 held (−40%) | $152.23 | $761K | -6.4% | — |
| Dec 17SEC | Leslie V NorwalkDirector | Sell Plan | 1,1906,239 held (−16%) | $155.09 | $185K | -8.2% | — |
| Dec 10SEC | Darin LippoldtGeneral Counsel | Sell Plan | 4,37643,405 held (−9%) | $159.65 | $699K | -10.8% | — |
| Dec 4SEC | Gary A LyonsDirector | Sell Plan | 15,000120,482 held (−11%) | $152.61 | $2.3M | -6.7% | — |
| Dec 2SEC | Eric BenevichChief Commercial Officer | Sell Plan | 5,97044,893 held (−12%) | $151.74 | $906K | -6.1% | — |
| Nov 26SEC | George J MorrowDirector | Sell Plan | 15,0007,068 held (−68%) | $143.37 | $2.2M | -0.6% | — |
| Nov 6SEC | William H RastetterDirector | Sell Plan | 18,00040,360 held (−31%) | $151.82 | $2.7M | -6.2% | — |
| Nov 4SEC | Kyle GanoCEO | Sell Plan | 300140,407 held (−0%) | $141.97 | $43K | +0.3% | — |
Insiders at NEUROCRINE BIOSCIENCES INC
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Kevin Charles GormanDirector | — | $37.8M | May 21, 2026 | — |
| Julie CookeChief Human Resources Officer | — | $5.8M | Jun 4, 2026 | — |
| Kyle GanoCEO | — | $4.9M | Jan 20, 2026 | — |
| Darin LippoldtGeneral Counsel | — | $4.2M | Jul 13, 2026 | — |
| Stephen A SherwinDirector | — | $4.1M | Jun 9, 2026 | — |
| Ingrid DelaetChief Regulatory Officer | — | $3.7M | Jul 13, 2026 | — |
| Jude OnyiaChief Scientific Officer | — | $3.5M | Jun 2, 2026 | — |
| William H RastetterDirector | — | $2.7M | Nov 6, 2025 | — |
| Richard F PopsDirector | — | $2.4M | May 18, 2026 | — |
| Gary A LyonsDirector | — | $2.3M | Dec 4, 2025 | — |
| George J MorrowDirector | — | $2.2M | Nov 26, 2025 | — |
| Leslie V NorwalkDirector | — | $2.0M | Jul 30, 2026 | — |
| Eric BenevichChief Commercial Officer | — | $1.2M | Sep 10, 2026 | — |
| David W. BoyerChief Corp. Affairs Officer | — | $739K | Sep 15, 2026 | — |
| Matt AbernethyCFO | — | $363K | Sep 15, 2026 | — |
NBIX stock: common questions
Are NEUROCRINE BIOSCIENCES INC insiders buying NBIX stock?
In the past 12 months, 0 insiders reported open-market purchases of NBIX worth $0.
Are NEUROCRINE BIOSCIENCES INC insiders selling NBIX stock?
15 insiders reported sales worth $77.9M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is NBIX's 52-week range?
Over the past year NBIX has traded between $123.10 and $185.50. It last closed at $142.44 on Oct 9, 2026.